09:06 AM EDT, 03/27/2025 (MT Newswires) -- Rigel Pharmaceuticals ( RIGL ) said Thursday that it has settled with Annora Pharma, Hetero Labs, and Hetero USA, resolving patent litigation related to its product Tavalisse.

Rigel said the litigation arose after Annora submitted an abbreviated new drug application to the US Food and Drug Administration seeking approval for a generic version of Tavalisse.

Rigel said the settlement allows Annora to be licensed to sell its generic version starting in Q2 2032 or earlier under certain conditions.

The settlement also ends all ongoing litigation between Rigel and Annora over Tavalisse patents in New Jersey, Rigel said.